Innovative and accredited continuing medical education for today’s practicing clinicians.
CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.
- Expert-led insights to improve patient outcomes
- Multi-modal courses to suit all learning styles
- Timely topics for relevant application to practice
- Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
- A commitment to collective mindfulness
Recent courses
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
|
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
|
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
|
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
|
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
|
Experts examine a patient case study as a way of translating guideline-based screening recommendations and current therapies that protect T2D patients from CKD progression in real-world practice.
|
An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
|
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.
|
Pharmacology for MDD is limited by low efficacy, delayed response, and side effects. Research on the pathophysiology of the disease that includes the glutamatergic system and GABA signaling is ushering in a new era for rapidly acting antidepressants.
|
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
|
Because of the multiple comorbidities and symptoms associated with Rett syndrome, clinicians are advised to implement a multidisciplinary approach to disease management with an eye toward new and emerging therapies on the horizon.
|
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies.
|
Pages
My Courses
Please login or create an account to view your activities.
Transcript
Please login or create an account to view your activities.